The pharma company Eli Lilly &Co has announced that their experimental once-weekly drug dulaglutide, which is being developed for treating patients with type 2 diabetes, has met its mid-stage trial targets.
The most recent trial for dulaglutide involved testing its impact on both heart rate and blood pressure, a requirement by the health regulator in the United States to ensure new drugs do not raise the chances of heart attacks. It involved 755 adults who had type 2 diabetes and were on one or more oral diabetes medication, and showed that its effect of the treatment on systolic blood pressure was about the same as that of a placebo. Of the participants in the study, around two thirds had a pre-existing diagnosis of hypertension.
The tests found that dulaglutide was also able to substantially lower or average blood glucose levels (or HbA1c) during the course of a three-month trial period as compared to a placebo at the end of 16 and 26 weeks. However, there were some typical adverse events recorded by the non-inferiority trial, from gastrointestinal problems such as nausea, diarrhoea and vomiting.
In addition, the company noted that a 1.5 mg dosage of dulaglutide presented statistically substantial reductions in average 24-hour systolic blood pressure as compared to a placebo during superiority testing.

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…

Top diabetes professor drafts risk assessment document for frontline COVID-19 staff

The health and wellbeing of frontline NHS staff has been prioritised among…